Skip to main content

Table 3 Histological and molecular characteristics

From: The association between smoking and breast cancer characteristics and outcome

Population (num) Histologya Grade ER PR Ki67 (%) P53 (%) Angiolymphatic invasion PNI
IDC (%) ILC (%) Other (%) P Mean (SD) P Mean (SD) P Mean (SD) P Mean (SD) P Mean (SD) P yes (%) P yes (%) P
All (662) 80.8 12.4 6.8 - 2.02 (0.59) - 2.47 (0.57) - 1.47 (1.19) - 16 (14) - 7.0 (17.0) - 6.0 - 4.4 -
Hx smokingb      2   2.47   1.51   16.0   6.0      
smokingb 80.3 13.9 5.8   (0.59)   (0.57)   (1.49)   (13.0)   (17.0)   7.3   5.5  
Yes (173) 80.0 12.5 7.5 0.701 2.04 0.535 2.47 0.97 1.48 0.805 16.0 0.854 7.0 0.582 5.4 0.388 3.8 0.358
No (439)      (0.6)   (0.58)   (1.07)   (14.0)   (17.0)      
Current      2.02   2.39   1.4   17.0   7.0      
smokingb 81.2 15.8 3.0   (0.58)   (0.59)   (1.08)   (15.0)   (18.0)   10.4   8.3  
Yes (101) 79.7 12.4 7.9 0.16 2.02 0.975 2.49 0.118 1.51   16.0 0.696 7.0 0.879 5.1 0.045 3.5 0.031
No (508)      (0.6)   (0.58)   (1.22) 0.41 (14.0)   (17.0)      
Number of pack years (PY)
PY2 0–29      2.03   2.47   1.52   16.0   7.0      
(518) 79.6 12.7 7.7   (0.6)   (0.58)   (1.22)   (14.0)   (17.0)   6.0   4.0  
PY > =30 84.9 12.1 3.0 0.365 2.0 0.712 2.4   1.27   14.0   5.0 0.523 7.7 0.609 7.7 0.18
(66)      (0.53)   (0.62) 0.377 (1.03) 0.112 (12.0) 0.225 (16.0)      
  1. aOther subtype histology includes: medullary, mucinous, papillary and tubular carcinoma
  2. bData regarding smoking was retrieved during the first visit at the oncologist clinic. Current smokers were defined as patients who actively smoked at the time of breast cancer diagnosis. Patients with history of smoking were defined as ever smoker
  3. - Abbreviations: ER estrogen receptor, Hx history, PNI perineural invasion, PR progesterone receptor, PY pack years
  4. - Data were not available for: Angiolymphatic invasion (n = 25); Grade (n = 116); Hx smoking (n = 49); Ki67 (n = 179); P53 (n = 287); PNI (n = 25); PY (n = 77); smoking status (n = 52)
  5. - Cohort included patients with ER positive, HER2 negative disease